14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:EARS
Delisted

Auris Medical Holding AG Stock Price (Quote)

$0.750
-0.0010 (-0.133%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 27th May 2022 EARS stock ended at $0.750. This is 0.133% less than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 10.68% from a day low at $0.740 to a day high of $0.82.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Auris Medical Holding AG prices

Date Open High Low Close Volume
Feb 20, 2019 $0.363 $0.375 $0.360 $0.360 800 761
Feb 19, 2019 $0.380 $0.380 $0.362 $0.375 682 491
Feb 15, 2019 $0.367 $0.379 $0.360 $0.373 793 655
Feb 14, 2019 $0.379 $0.394 $0.364 $0.370 1 573 785
Feb 13, 2019 $0.430 $0.470 $0.378 $0.394 11 585 627
Feb 12, 2019 $0.370 $0.373 $0.340 $0.361 1 673 714
Feb 11, 2019 $0.410 $0.420 $0.348 $0.355 4 822 950
Feb 08, 2019 $0.444 $0.450 $0.430 $0.437 494 033
Feb 07, 2019 $0.431 $0.450 $0.430 $0.431 432 799
Feb 06, 2019 $0.430 $0.450 $0.423 $0.450 892 221
Feb 05, 2019 $0.469 $0.470 $0.423 $0.429 1 133 343
Feb 04, 2019 $0.450 $0.475 $0.440 $0.453 1 010 859
Feb 01, 2019 $0.440 $0.450 $0.425 $0.445 1 664 318
Jan 31, 2019 $0.440 $0.440 $0.420 $0.422 561 958
Jan 30, 2019 $0.422 $0.440 $0.420 $0.430 907 953
Jan 29, 2019 $0.420 $0.444 $0.410 $0.433 1 416 880
Jan 28, 2019 $0.450 $0.450 $0.420 $0.428 935 932
Jan 25, 2019 $0.440 $0.450 $0.415 $0.441 843 997
Jan 24, 2019 $0.431 $0.445 $0.405 $0.440 1 909 959
Jan 23, 2019 $0.530 $0.535 $0.428 $0.450 12 372 237
Jan 22, 2019 $0.395 $0.409 $0.385 $0.398 792 109
Jan 18, 2019 $0.420 $0.430 $0.380 $0.409 1 530 489
Jan 17, 2019 $0.438 $0.446 $0.410 $0.417 1 102 554
Jan 16, 2019 $0.500 $0.500 $0.410 $0.438 4 002 191
Jan 15, 2019 $0.450 $0.545 $0.440 $0.465 8 217 181
Click to get the best stock tips daily for free!

About Auris Medical Holding AG

Auris Medical Holding AG Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss; and other pre-clinical stage products comprising AM-102 and AM-123. It has... EARS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT